Israel Englander Abb Vie Inc. Put Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $79 Million - $96.1 Million	-482,200 Reduced 47.5%	532,900 $105 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $10.4 Million - $12.1 Million	67,100 Added 7.08%	1,015,100 $174 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $40.3 Million - $45.9 Million	-252,000 Reduced 21.0%	948,000 $173 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $57.9 Million - $65.2 Million	420,600 Added 53.96%	1,200,000 $186 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $54.3 Million - $67.6 Million	-410,100 Reduced 34.48%	779,400 $105 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $52.5 Million - $60.5 Million	-363,100 Reduced 23.39%	1,189,500 $190 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $83 Million - $99.6 Million	600,400 Added 63.05%	1,552,600 $251 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $16.3 Million - $18.7 Million	-121,600 Reduced 11.32%	952,200 $128 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.